AMGN vs GSK
Amgen and GSK plc, both Healthcare
Amgen is the larger company at $182B against $102B. Over the past year AMGN returned +59% against +42% for GSK.
| Figure | AMGN | GSK |
|---|---|---|
| Last close | $440 | $51.44 |
| Market cap | $182B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.4 | n/a |
| Dividend yield | 2.2% | n/a |
| 1-year return | +59% | +42% |
| 5-year return | +113% | +57% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
GSK plc
Open these two in the interactive comparison to add more names, change the period or read the correlation.